NCT03674476 is a Phase 1 clinical trial of BMS-986036 in NAFLD, sponsored by Bristol-Myers Squibb.

Who is sponsoring NCT03674476?

NCT03674476 is sponsored by Bristol-Myers Squibb.

What drugs are being tested in NCT03674476?

Interventions in NCT03674476: BMS-986036.

What condition does NCT03674476 study?

NCT03674476 studies NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis.

Is NCT03674476 still recruiting?

NCT03674476 is currently completed. Last updated 8 October 2019.

Last reviewed 2019-10-08 · How we verify

NCT03674476

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function

Completed Phase 1 Last updated 8 October 2019

What this trial tests

Phase 1 trial testing BMS-986036 in NAFLD in 40 participants. Completed in 24 June 2019.

Timeline

11 September 2018

Primary endpoint
24 June 2019

24 June 2019

Quick facts

Lead sponsor	Bristol-Myers Squibb
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	11 September 2018
Primary completion	24 June 2019
Estimated completion	24 June 2019
Sites	4 locations across Hungary, Czechia

Drugs / interventions tested

BMS-986036 — full drug profile →

Conditions studied

NAFLD — all drugs for NAFLD →
Nonalcoholic Fatty Liver Disease — all drugs for Nonalcoholic Fatty Liver Disease →
Nonalcoholic Steatohepatitis — all drugs for Nonalcoholic Steatohepatitis →

Sponsor

Bristol-Myers Squibb — full company profile →

Who can join

Adults 21 to 75, any sex, with NAFLD or Nonalcoholic Fatty Liver Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an investigational study to evaluate the experimental medication BMS-986036 in participants with different levels of kidney function.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Hepatic fibrosis: Targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines.
Gong L, Wei F, Gonzalez FJ, Li G. · · 2023 · cited 28× · PMID 36626642 · DOI 10.1097/hep.0000000000000182
The role of nonmyocardial cells in the development of diabetic cardiomyopathy and the protective effects of FGF21: a current understanding.
Zhang T, Jiang D, Zhang X, Chen L, et al · · 2024 · cited 4× · PMID 39327594 · DOI 10.1186/s12964-024-01842-0

Verify or expand the search:

Other trials of BMS-986036

Trials testing the same drug.

NCT04649710 — A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Partic · Phase 1 · withdrawn
NCT04634149 — A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function a · Phase 1 · completed
NCT04493567 — Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Admi · Phase 1 · completed
NCT03486899 — A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibro · Phase 2 · completed
NCT03486912 — A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis · Phase 2 · completed

Other recruiting trials for NAFLD

Currently open trials in the same condition.

NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting
NCT06661655 — Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients · NA · recruiting
NCT07093346 — The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patient · NA · recruiting
NCT06879236 — Secondary and Tertiary Digital Prevention of Non-alcoholic and Dysmetabolic Liver Disease · recruiting
NCT06888310 — Optimizing Noninvasive assessMent Of DysmEtabolic Compensated Advanced Liver Disease · NA · recruiting

Other Bristol-Myers Squibb trials

Trials by the same sponsor.

NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03674476 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
Last refreshed: 8 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03674476.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing